In clinical practice, breast cancer is divided according to three biomarkers, estrogen receptor (ER), progesterone receptor (PR) and Her2; into positive hormonal receptors (ER+), HER2+ and triple negative (TNBC), characterized by a lack of expression of these receptors. This evidence concerns the gene NR4A1 and breast carcinoma.